Download PDF
Arthritis und Rheuma 2017; 37(04): 250-259
DOI: 10.1055/s-0037-1618435
Kinderrheumatologie/GKJR-Kommission PRO-KIND: Protokolle
Schattauer GmbH

Harmonisierung der Diagnostik und Therapie der systemischen juvenilen idiopathischen Arthritis in Deutschland

Prozessbeschreibung und KernaussagenThe German PRO-KIND project group on SJIAstatus report 2017
C. H. Hinze
1   Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster
,
D. Holzinger
1   Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster
,
E. Lainka
2   Klinik für Kinder-und Jugendmedizin, Universitätskinderklinik Essen, Essen
,
J.-P. Haas
3   Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
,
F. Speth
4   Klinik für Kinder- und Jugendheilkunde, Universitätsmedizin Rostock, Rostock
,
T. Kallinich
5   Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie, Charité Berlin, Berlin
,
N. Rieber
6   Kinderklinik München Schwabing, Klinik und Poliklinik für Kinder- und Jugendmedizin, Klinikum Schwabing, StKM GmbH und Klinikum rechts der Isar (AöR), Technische Universität München, München
,
M. Hufnagel
7   Klinik für Allgemeine Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Freiburg
,
A. F. Jansson
8   Abteilung für Rheumatologie & Immunologie, Dr. von Haunersches Kinderspital, Klinikum der Universität München, München
,
C. Hedrich
9   Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Dresden
,
H. Winowski
10   Klinik für Kinder- und Jugendrheumatologie, St. Josef-Stift Sendenhorst, Sendenhorst
,
G. Horneff
11   Allgemeine Kinder- und Jugendmedizin, Kinderklinik Sankt Augustin, Asklepios Klinik Sankt Augustin, Sankt Augustin
,
D. Föll
1   Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster
12   für die PRO-KIND SJIA-Projektgruppe
› Author Affiliations
Further Information

Publication History

Publication Date:
28 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nature reviews Rheumatology 2011; 7 (07) 416-426.
    CrossrefPubMedGoogle Scholar
  • 2 Calabro JJ, Marchesano JM. Fever associated with juvenile rheumatoid arthritis. The New England journal of medicine 1967; 276 (01) 11-18.
    CrossrefPubMedGoogle Scholar
  • 3 Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Annals of the rheumatic diseases 2012; 71 (09) 1437-1439.
    CrossrefPubMedGoogle Scholar
  • 4 Behrens EM, Beukelman T, Gallo L. et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). The Journal of rheumatology 2008; 35 (02) 343-348.
    PubMedGoogle Scholar
  • 5 Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S. et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still‘s disease. The Journal of rheumatology 2001; 28 (02) 322-329.
    PubMedGoogle Scholar
  • 6 Yamaguchi M, Ohta A, Tsunematsu T. et al. Preliminary criteria for classification of adult Still‘s disease. The Journal of rheumatology 1992; 19 (03) 424-430.
    PubMedGoogle Scholar
  • 7 Ansell BM. Problems of corticosteroid therapy in the young. Proceedings of the Royal Society of Medicine 1968; 61 (03) 281-282.
    PubMedGoogle Scholar
  • 8 Picco P, Gattorno M, Buoncompagni A, Pistoia V, Borrone C. 6-methylprednisolone ‚mini-pulses‘: a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Scandinavian journal of rheumatology 1996; 25 (01) 24-27.
    CrossrefPubMedGoogle Scholar
  • 9 De Benedetti F, Brunner HI, Ruperto N. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. The New England journal of medicine 2012; 367 (25) 2385-2395.
    CrossrefPubMedGoogle Scholar
  • 10 Quartier P, Allantaz F, Cimaz R. et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Annals of the rheumatic diseases 2011; 70 (05) 747-754.
    CrossrefPubMedGoogle Scholar
  • 11 Ruperto N, Brunner HI, Quartier P. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. The New England journal of medicine 2012; 367 (25) 2396-2406.
    CrossrefPubMedGoogle Scholar
  • 12 Beukelman T, Patkar NM, Saag KG. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care & research 2011; 63 (04) 465-482.
    CrossrefPubMedGoogle Scholar
  • 13 DeWitt EM, Kimura Y, Beukelman T. et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis care & research 2012; 64 (07) 1001-1010.
    Google Scholar
  • 14 Ringold S, Weiss PF, Beukelman T. et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis and rheumatism 2013; 65 (10) 2499-2512.
    CrossrefPubMedGoogle Scholar
  • 15 Vastert SJ, de Jager W, Noordman BJ. et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis & rheumatology (Hoboken, NJ) 2014; 66 (04) 1034-1043.
    CrossrefPubMedGoogle Scholar
  • 16 Dueckers G, Guellac N, Arbogast M. et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clinical immunology (Orlando, Fla) 2012; 142 (02) 176-193.
    CrossrefPubMedGoogle Scholar
  • 17 Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. Arthritis & rheumatology (Hoboken, NJ) 2014; 66 (06) 1405-1413.
    CrossrefPubMedGoogle Scholar
  • 18 Group OLo EW. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) 2009. Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-levelsevidence-march-2009/
  • 19 Koolman AH, Kamphuis SS, Weggelaar NM. et al. [Children with fever peaks and bone and joint pain: systemic juvenile idiopathic arthritis or acute lymphoblastic leukemia after all?]. Nederlands tijdschrift voor geneeskunde 2002; 146 (35) 1613-1616.
    PubMedGoogle Scholar
  • 20 Suri D, Ahluwalia J, Sachdeva MU. et al. Arthritic presentation of childhood malignancy: beware of normal blood counts. Rheumatology international 2011; 31 (06) 827-829.
    CrossrefPubMedGoogle Scholar
  • 21 Tamashiro MS, Aikawa NE, Campos LM. et al. Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset. Clinics (Sao Paulo, Brazil) 2011; 66 (10) 1665-1669.
    PubMedGoogle Scholar
  • 22 Trapani S, Grisolia F, Simonini G. et al. Incidence of occult cancer in children presenting with musculoskeletal symptoms: a 10-year survey in a pediatric rheumatology unit. Seminars in arthritis and rheumatism 2000; 29 (06) 348-359.
    CrossrefPubMedGoogle Scholar
  • 23 Kallinich T, Lainka E, Berner R, Niehues T. Leitlinie der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Kinder- und Jugendmedizin: Fieber unklarer Genese 2013 [cited 2016]. Available from: http://www.awmf.org/leitlinien/detail/ll/027-053.html
  • 24 Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?. Rheumatology (Oxford, England) 2005; 44 (11) 1350-1353.
    CrossrefPubMedGoogle Scholar
  • 25 Ombrello MJ, Remmers EF, Tachmazidou I. et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America 2015; 112 (52) 15970-15975.
    CrossrefPubMedGoogle Scholar
  • 26 Put K, Vandenhaute J, Avau A. et al. Inflammatory gene expression profile and defective IFN-gamma and granzyme K in natural killer cells of systemic juvenile idiopathic arthritis patients. Arthritis & rheumatology (Hoboken, NJ) 2016
    Google Scholar
  • 27 Gohar F, Kessel C, Lavric M. et al. Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?. Arthritis research & therapy 2016; 18: 163
    CrossrefPubMedGoogle Scholar
  • 28 Holzinger D, Frosch M, Kastrup A. et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Annals of the rheumatic diseases 2012; 71 (06) 974-980.
    CrossrefPubMedGoogle Scholar
  • 29 Wittkowski H, Frosch M, Wulffraat N. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis and rheumatism 2008; 58 (12) 3924-3931.
    CrossrefPubMedGoogle Scholar
  • 30 Nigrovic PA, Mannion M, Prince FH. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis and rheumatism 2011; 63 (02) 545-555.
    CrossrefPubMedGoogle Scholar
  • 31 Ruperto N, Quartier P, Wulffraat N. et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and rheumatism 2012; 64 (02) 557-567.
    CrossrefPubMedGoogle Scholar
  • 32 Passo MH, Taylor J. Quality improvement in pediatric rheumatology: what do we need to do?. Current opinion in rheumatology 2008; 20 (05) 625-630.
    CrossrefPubMedGoogle Scholar